



(12) Translation of
European patent specification

(11) NO/EP 3191513 B1

NORWAY

(19) NO
(51) Int Cl.
C07K 16/24 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2020.10.12
(80)	Date of The European Patent Office Publication of the Granted Patent	2020.06.24
(86)	European Application Nr.	15760590.8
(86)	European Filing Date	2015.08.28
(87)	The European Application's Publication Date	2017.07.19
(30)	Priority	2014.09.08, US, 201462047248 P 2014.12.12, US, 201462091150 P 2015.05.29, US, 201562168007 P 2015.07.13, US, 201562191690 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
(73)	Proprietor	Cephalon, Inc., 41 Moores Road P.O. Box 4011, Frazer, PA 19355, USA
(72)	Inventor	BRUSSELLE, Guy, Begonialaan 28, 9840 De Pinte, Belgium O'BRIEN, Christopher, 110 Chinaberry Drive, Lafayette Hill, PA 19444, USA ZANGRILLI, James, 1606 Chestnut Street Unit 2, Philadelphia, PA 19103, USA SHAH, Tushar, 124 Hilcrest Road, Flemington, NJ 08022, USA
(74)	Agent or Attorney	TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54)	Title	USE OF RESLIZUMAB TO TREAT MODERATE TO SEVERE EOSINOPHILIC ASTHMA
(56)	References Cited:	WO-A2-2009/120927 WO-A2-2012/083132 WO-A2-2011/156000 MARIO CASTRO ET AL: "Reslizumab for Poorly Controlled, Eosinophilic Asthma", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE., vol. 184, no. 10, 15 November 2011 (2011-11-15), pages 1125-1132, XP055229732, US ISSN: 1073-449X, DOI: 10.1164/rccm.201103-0396OC

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav**1.** Reslizumab for anvendelse i behandlingen av eosinofil astma, hvor:

5 3mg/kg reslizumab er tilført intravenøst én gang hver 4 uke til en pasient sammen
med en langtidsvirkende beta-2 adrenoceptor agonist (LABA) og et inhalert
kortikosteroid, hvor det inhalerte kortikosteroidet omfatter > 500 µg Flutikason, >
440 µg Mometason, > 800 µg Budesonid, > 320 µg Ciclesonid, > 400 µg
10 Beklometason, eller > 2000 µg Triamcinolon, hvor nevnte pasient har nivåer av
eosinofile i blodet lik med eller større enn 400/µl og, før anvendelsen, ble
pasientens symptomer utilstrekkelig kontrollert med nevnte langtidsvirkende beta-
2 adrenoceptor agonist (LABA) og inhalert kortikosteroid og
hvor, i de 12 månedene før anvendelsen, pasienten hadde minst én astma-
15 forverring som krevet oral, intramuskulær, eller intravenøs kortikosteroid
anvendelse i mer enn eller lik med 3 dager.

2. Reslizumab for anvendelse I henhold til krav 1, hvor det inhalerte kortiko-steroidet
er > 500 µg flutikason.